What's Happening?
Dizal will present new clinical data from its non-small cell lung cancer (NSCLC) pipeline at the 2026 ASCO Annual Meeting. The presentations will feature investigational assets ZEGFROVY® (sunvozertinib), golidocitinib, and DZD6008, including two oral
presentations and a poster. The Phase 3 WU-KONG28 study of ZEGFROVY, selected as a Late-Breaking Abstract, compares sunvozertinib to chemotherapy in NSCLC patients with EGFR exon20ins mutation. Dizal's data highlights advancements in NSCLC treatment, showcasing the efficacy of its novel EGFR inhibitors and JAK1 inhibitor combinations.
Why It's Important?
Dizal's presentations at ASCO 2026 are significant for advancing NSCLC treatment options, particularly for patients with challenging EGFR mutations. The positive results from the WU-KONG28 study demonstrate ZEGFROVY's potential as a preferred treatment for newly diagnosed lung cancer patients with EGFR exon20ins mutation. The company's focus on novel EGFR inhibitors and JAK1 inhibitor combinations could lead to improved outcomes and expanded treatment options for NSCLC patients. Dizal's commitment to developing innovative therapies highlights the ongoing progress in addressing unmet needs in lung cancer care.
